Abbott Laboratories $38.93

up +0.55


17/4/2014 06:40 PM  |  NYSE : ABT  
Industries : Health Services / Medical Appliances & Equipment
Get Trend Analysis Icon Get ABT Trend Analysis - it has underperformed the S&P 500 by 16%

Partner Headlines

  1. Morgan Stanley Sees Attractive Entry Point for Abbott Laboratories

    Benzinga
  2. Abbott Labs Q1 sales, EPS fall

    IBD
  3. Market Wrap For April 16: Markets Hold On To Gains An Positive Yellen Comments ...

    Benzinga
  4. Abbott Q1 Performance Slips, But EPS Tops Estimates

    IBD
  5. Stock Futures In Positive Mode; Yahoo Rockets On Alibaba Boost

    IBD
  6. UPDATE: Abbott Posts Upbeat Q1 Earnings

    Benzinga
  7. Earnings Scheduled For April 16, 2014

    Benzinga
  8. Stocks To Watch For April 16, 2014

    Benzinga
  9. Intuitive Surgical Made Sci-Fi Dreams A Reality

    IBD
  10. Abbott Completes Enrollment of Absorb Randomized Clinical Trials in the ...

    Benzinga
  11. Absolute and Relative Valuation Models Indicate the Same: Abbot Is a Buy

    GuruFocus
  12. We Are Confident About Baxter's Plan to Create Two Separate Health Care ...

    GuruFocus
  13. Baxter Splitting In Effort To 'Unlock Trapped Value'

    IBD
  14. TripAdvisor: Yelp of Travel Looks Too Pricey

    YCharts
  15. Which Pharmas Can Keep Up Dividend-Buybacks?

    YCharts
  16. Lountzis Asset Management Comments on Abbott Laboratories

    GuruFocus
  17. Abbott Capturing Incremental Market Share

    GuruFocus
  18. Abbvie's Humira Continues to be a Powerful Catalyst for Growth

    GuruFocus
  19. Morgan Stanley Sees 2015 Numbers Going Higher for Abbott Laboratories

    Benzinga
  20. AbbVie’s Testosterone: Impact of Health Concerns

    YCharts
  21. Morgan Stanley Maintains on Abbott Laboratories

    Benzinga
  22. Abbott EPS meets, sales miss

    IBD
  23. Abbott Labs Q4 Sales Miss Estimates; Earnings In Line

    IBD
  24. Earnings Scheduled For January 22, 2014

    Benzinga
  25. Stocks To Watch For January 22, 2014

    Benzinga
  26. UPDATE: Morgan Stanley Upgrades Abbott Laboratories

    Benzinga
  27. Diamond Hill Capital Comments on Abbott Laboratories

    GuruFocus
  28. Morgan Stanley Upgrades Abbott Based on Reacceleration

    Benzinga
  29. Dividend Aristocrat Johnson & Johnson Offers Growth

    IBD
  30. Drugmakers End Louisiana Suit Over Inflated Prices

    YCharts
  31. Johnson & Johnson (JNJ) Dividend Stock Analysis

    GuruFocus
  32. AbbVie Hepatitis C Treatment Shines In Latest Trials

    IBD
  33. Investing in Generation Y and the Next Great Baby Boom

    GuruFocus
  34. New Statin Rules: Which Drugmakers Had Ties?

    YCharts
  35. Johnson & Jonhson Unit Could Fetch Over $4 Billion in Sale

    Benzinga
  36. AbbVie’s AndroGel Testosterone Hit By Heart Study

    YCharts
  37. Where J&J $2.2B Settlement Fits Among Biggest

    YCharts
  38. AbbVie beats on Humira sales

    IBD
  39. AbbVie Earnings Beat Estimates; Street Eyes HCV Drugs

    IBD
  40. Generic Drug Industry: Top Five Players

    YCharts
  41. Starbucks Comes Under Official Chinese Criticism For Prices

    Benzinga
  42. 13 Companies Creating Real Wealth with Higher Cash Dividends

    GuruFocus
  43. 4 Big Players With Recent Dividend Growth To Consider

    GuruFocus
  44. Barron's Recap: Return Of The Bulls

    Benzinga
  45. Detecting Malaria Using a Cell's Electric Vibe

    FoxBusiness
  46. Market Primer: Thursday, October 17: US Debt Deal Kicks The Can

    Benzinga
  47. Abbott Q3 profit beats views

    IBD
  48. Stocks Open Higher, Trade Mixed; Piper Jaffray, Abbott Labs Rise

    IBD
  49. UPDATE: Abbott Posts Upbeat Q3 Profit, Lifts Dividend

    Benzinga
  50. Earnings Scheduled For October 16, 2013

    Benzinga
Trading Center